ABSTRACT

Chronic myeloid leukemia (CML) is a malign clonal hematopoietic disease. BCR-ABL1 is a fusion gene and plays role on molecular pathogenesis of CML. This protein encodes a tyrosine kinase. GAB2 and GRB2 are its modulators of this tyrosine kinase which has effects on AKT, ERK, STAT pathways. STI571 (imatinib mesilat) which is used for CML treatment, is a tyrosine kinase inhibitor. Genistein is a herbal flavonoid which has estrogenic effects besides tyrosine kinase inhibitor activity. In this study, we aimed to determine the effect of STI571 and genistein application for intercellular signal transduction pathways at protein level on the K562 cells.

K562 cells were cultured at standard conditions. The cytotoxic concentrations of STI571 and genistein were determined with MTT. STI571 and genistein were applied alone and in combination at 24 and 48 hours. The protein levels were determined by ELISA method. The data were evaluated statistically.

There was no statistically significant difference of protein levels with STI571 and genistein alone and in combination.

In this study, the effects of STI571 and genistein were evaluated on a wide protein panel. It is well known STI571 and genistein have tyrosine kinase inhibitory effects. However, in previous reports there are controversial results on the protein levels of both agents. Our results showed that the combination of STI571and genistein have no significant effect on the protein levels.